Get the Stockscreener App
3.945
0.38%
0.015
Cytomx Therapeutics Inc stock is traded at $3.945, with a volume of 2.67M.
It is up +0.38% in the last 24 hours and up +19.55% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$3.93
Open:
$3.855
24h Volume:
2.67M
Relative Volume:
0.72
Market Cap:
$650.58M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-197.25
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+18.83%
1M Performance:
+19.55%
6M Performance:
+391.90%
1Y Performance:
+290.59%
1-Day Range:
$3.71
$4.18
1-Week Range:
$3.22
$4.18
52-Week Range:
$0.40
$4.18
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.945 | 648.11M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.49 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.45 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.24 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.56 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX stock rises after initial data shows CX-801 working as designed By Investing.com - Investing.com South Africa
CytomX Therapeutics, Inc. to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
CytomX reports tumor-selective activation in melanoma treatment trial - Investing.com
CytomX Therapeutics Announces Phase 1 Data for CX-801 Highlighting Tumor-Selective Interferon Signaling in Advanced Melanoma Patients - Quiver Quantitative
CytomX (NASDAQ: CTMX) to present CX-801 Phase 1 biomarker data on interferon signaling - Stock Titan
What dividend safety rating applies to CytomX Therapeutics Inc. (6C1) stockJuly 2025 Decliners & Verified Swing Trading Watchlists - newser.com
CytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week HighStill a Buy? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
How CytomX Therapeutics Inc. stock compares to market leadersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockGlobal Markets & Reliable Intraday Trade Plans - newser.com
Can CytomX Therapeutics Inc. stock reach $100 price targetEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow Jones2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Visual analytics tools that track CytomX Therapeutics Inc. performanceJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy call2025 Trading Recap & Fast Gaining Stock Strategy Reports - newser.com
How to integrate CytomX Therapeutics Inc. into portfolio analysis toolsJuly 2025 Review & Weekly Watchlist for Consistent Profits - newser.com
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stock2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Will CytomX Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
What analyst consensus implies for CytomX Therapeutics Inc. (6C1) stockJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Is CytomX Therapeutics Inc. (6C1) stock a buy on weakness2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Why retail traders accumulate CytomX Therapeutics Inc. (6C1) stockAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Using data filters to optimize entry into CytomX Therapeutics Inc.Market Trend Report & Reliable Intraday Trade Plans - newser.com
How CytomX Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Published on: 2025-11-02 12:38:04 - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly data2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Using Ichimoku Cloud for CytomX Therapeutics Inc. technicalsQuarterly Portfolio Report & Long-Term Capital Growth Strategies - newser.com
How CytomX Therapeutics Inc. stock reacts to oil pricesJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Why analysts maintain buy rating on CytomX Therapeutics Inc. (6C1) stockShort Setup & Real-Time Volume Triggers - newser.com
What drives CytomX Therapeutics Inc 6C1 stock priceMarket Sentiment Report & Trusted Financial Advisors at No Cost - earlytimes.in
Is CytomX Therapeutics Inc. (6C1) stock considered safe havenTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Building trade automation scripts for CytomX Therapeutics Inc.2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):